expert roundtables by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
Dopamine receptor–blocking agents (DRBAs) are thought to lead to the development of tardive dyskinesia (TD) through mechanisms that involve postsyn......READ MORE
The emergence of vesicular monoamine transporter 2 (VMAT2) inhibitors has ushered in a new era in the management of tardive dyskinesia (TD). In cli......READ MORE
expert roundtables by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
The introduction of the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine has marked a sea change in the manage......READ MORE
expert roundtables by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
Tardive dyskinesia (TD) can be chronic and irreversible, even among patients who have discontinued treatment with dopamine receptor–blocking agents......READ MORE
patient care perspectives by Leslie Citrome, MD, MPH
The risk of tardive dyskinesia (TD) from second-generation antipsychotics appears to be lower than with first-generation agents, but the full cumul......READ MORE
patient care perspectives by Leslie Citrome, MD, MPH
Although tardive dyskinesia (TD) can impair psychosocial and physical functioning in people of all ages, older individuals may be more severely imp......READ MORE
